ENA 2018

Tue 13 Nov
Auditorium - 10:00 - 12:00

Clinical Trial Methodology Workshop: Exploratory Combination Immunotherapy Trials: How to Design Effective Phase I or II Trials

Chair: C. Blank (Netherlands)

Chair: S. Turajlic (United Kingdom)

10:00 Immune contexture and precision medicine
Speaker: J. Galon (France)

10:20 Profiling the tumor microenvironment in the era of precision medicine
Speaker: A. Cesano (USA)

10:40 Neoadjuvant immunotherapy as pathway towards personalized therapies
Speaker: C. Blank (Netherlands)

11:00 Debate: Focus on PD1 naive setting vs PD1 refractory setting

---

Tue 13 Nov
Auditorium - 13:00 - 13:05

Opening Ceremony: Opening Remarks

13:00 Welcome to the 30th Molecular Targets and Cancer Therapeutics Symposium
Chair: C. Swanton (United Kingdom)

Tue 13 Nov
Auditorium - 13:05 - 13:50

Michel Clavel Lecture: RAS Targeting

Chair: C. Swanton (United Kingdom)

13:05 RAS targeting
Speaker: J. Downward (United Kingdom)

Tue 13 Nov
Auditorium - 13:50 - 14:35

30th Anniversary Keynote Lecture: Pancreatic cancer - A “hacked" regenerative programme

Chair: A. Ribas (USA)

13:50 Pancreatic cancer - A “hacked" regenerative programme
Speaker: D.D. Von Hoff (USA)

Tue 13 Nov
Auditorium - 15:05 - 16:50

Plenary Session 1: Should we be conducting more Genomics Driven, Multi-Arm Clinical Trials?

Chair: F. André (France)

Chair: F. Meric-Bernstam (USA)

15:05 Introduction to the session
Chair: F. Meric-Bernstam (USA)

15:10 NCI-MATCH
Speaker: K. Flaherty (USA)

15:30 SPECTA programme
Speaker: M. Morfouace (Belgium)

15:50 Lung Cancer Study
Speaker: G. Middleton (Ireland)

16:10 AZD5363 in Patients (Pts) with Tumors with AKT Mutations: NCI-MATCH Subprotocol EAY131-Y, A Trial of the ECOG-ACRIN Cancer Research Group (EAY131-Y)

K. Kalinsky|, F. Hong|, C.K. McCourt|, J.C. Sachdev|, E.P. Mitchell|, J.A. Zwiebel|, L.A. Doyle|, L.M. McShane|, S. Li|, R.J. Gray|, L.V. Rubinstein|, D. Patton|, P.M. Williams|, S.R. Hamilton|, B.A. Conley|, P.J. O'Dwyer|, L.N. Harris|, C.L. Arteaga|, A.P. Chen|, K.T. Flaherty|

16:25 Panel Discussion

Health economist
Panel: T. Fojo (USA)

Health economist
Panel: R. Sullivan (United Kingdom)

Regulator
Panel: R. Giuliani (Italy)

Industry
Panel: S. Galbraith (United Kingdom)

Academia
Panel: R. Salgado (Belgium)

Tue 13 Nov
Exhibition Hall -

Poster Session: DNA Repair Modulation

PB-001 SY-1365, a selective CDK7 inhibitor, enhances carboplatin activity in ovarian cancer cell lines and xenografts, and transcriptionally inhibits homologous recombination repair (HRR) genes
L. Johannessen|, S. Hu|, N. Ke|, N. Rajagopal|, D. Orlando|, S. Alnemy|, J. Carulli|, G. Hodgson|, E. di Tomaso|

PB-002 Phase II trial of pembrolizumab in patients with solid tumors functionally competent or deficient for the Fanconi Anemia repair pathway
M. Villalona|, J.P. Diaz|, W. Duan|, Z. Diaz|, E.D. Schroeder|, S. Aparo|, F. Vargas Madueno|, A. Alonso|, S. Cuitiva|, F. Albrecht|, S. Venkatappa|, V. Guardiola|, M. Troner|, G. Walker|, G. Narasimhan|

PB-003 PARP inhibitors activate cancer cell-intrinsic immunity via cGAS/STING in ERCC1- and BRCA1-defective contexts
R. Chabanon|, G. Muirhead|, D. Krastev|, J. Adam|, M. Garrido|, D. Morel|, N. Dorvault|, T. Eychenne|, C. Hénon|, R. Marlow|, C. Massard|, A. Ashworth|, S. Pettitt|, S. Haider|, A. Tutt|, A. Marabelle|, J.C. Soria|, C. Lord|, S. Postel-Vinay|

PB-004

Investigating the interaction of the ATR inhibitor, AZD6738, with platinum chemotherapy
S. Hall|, A. Lau|, E. Dean|, E. Martin|, C. Huins|, C. Ottley|, G. Veal|, Y. Drew|

PB-005 Targeting DNA-PK along with irradiation in head and neck cancer preclinical models suggests an HPV/p53 status-related pattern of response
S.M. Roth|, D.M. Aebersold|, M. Medová|, Y. Zmmer|

PB-006 Inhibition of dUTPase induces a state of nucleotide pool and DNA repair imbalance that sensitises triple negative breast cancer cells to standard of care chemotherapies
C. Davison|, C. Knowlson|, K. Savage|, R. Wilson|, K. Mulligan|, P. Wilson|, P. Johnston|, R. Ladner|, M. LaBonte Wilson|

PB-007 talazoparib and decitabine: a promising combination for BRCA-mutated cancers treatment
R. Pacaud|, S. Thomas|, E. Roche|, N. Pawlowska|, M. Dhawan|, P. Munster|

PB-008 BRCA reversion mutations in circulating cell-free tumour DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma (HGOC)
I.A. McNeish , K.K. Lin , M.R. Radke , A.M. Oza , A. Oaknin , I. Ray-Coquard , A.V. Tinker , E. Helman , J. Isaacson , L. Maloney , D.M. O'Malley , S.K. Chambers , S.H. Kaufmann , C Scott, G.E. Konecny , R.L. Coleman , H. Giordano , J.D. Brenton , T.C. Harding , E.M. Swisher

PB-009 Finding determinants of PARP inhibitor resistance using genome-wide and focused CRISPR screens
S. Pettitt|, D. Krastev|, F. Song|, J. Frankum|, R. Brough|, I. Brandsma|, J.M. Lee|, E. Swisher|, A. Ashworth|, C. Lord|

PB-012 DNA repair and its guradian angel protein: computational/experimental study of RAD51/ss-DNA interaction
D. Marson|, M. Fermeglia|, E. Laurini|, S. Pricl|

PB-013 DNA-PK regulates the radiosensitivity of MET-addicted cancer cell lines via a novel MET phosphosite
J.P. Koch|, S.M. Roth|, A. Quintin|, J. Gavini|, E. Orlando|, M. Medo|, R. Aebersold|, D.M. Stroka|, D.M. Aebersold|, Y. Zimmer|, M. Medová|

PB-014 Development of tumor-targeted PARP inhibitors for the treatment of solid cancers
R. Aiello|, B. Ranjit|, D. Marshall|, J. Csengery|, P. Bourassa|, Q. Zhang|, B. Robinson|, L. Lopresti-Morrow|, J. Bechtold|, L. Tylaska|, R. Sundaram|, P. Hellsund|, P. Glazer|, V. Paralkar|

PB-015 A phase i study of the poly-adp ribose polymerase (PARP) inhibitor, niraparib (NIR), in combination with irinotecan (IRN) in patients with advanced ewing sarcoma: results of sarc025 arm 2

K. Zaki , K.V. Ballman , L.J. Hellman , B.C. Widemann , D.S. Hawkins , L. Mascarenhas , J.W. Glod , J Ji,Y Zhang, B. Geoerger , J. Whelan , D. Reinke , S.R. Patel , R. Chugh , S.J. Strauss

PB-016 Less is more: subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors in vitro and in vivo
Z.U. Oo|, M. Proctor|, A. Stevenson|, D. Nazareth|, N. Haass|, J. Larsen|, B. Gabrielli|

PB-017 Measurement of SLFN11 protein in circulating tumor cells (CTCs) as a proposed liquid biopsy biomarker to predict response to DNA repair targeted therapies
L. Fernandez|, L. Chu|, R. Richardson|, R. Graf|, Y. Wang|, M. Landers|, R. Dittamore|

PB-018 Preclinical evaluation of the ATR inhibitor VE-821 alone and in combination with the PARP inhibitor olaparib in neuroblastoma
H. Southgate|, L. Chen|, N.J. Curtin |, D.A. Tweddle|

PB-020 Multiple deletions as a prognostic factor in metastatic colorectal cancer with chromothripsis
E. Skuja|, D. Kalniete|, M. Nakazawa-Miklasevica|, Z. Daneberga|, G. Purkalne|, E. Miklasevics|

PB-021 Characterization of small molecule inhibitors of ubiquitin specific peptidase 1 (USP1) as anti-cancer agents
E. Brenndörfer|, D. Jönsson|, K. Böhm|, A. Eneroth|, K. Acs|, I. Henderson|, M. Kullman-Magnusson|, C. Rydergård|, G. Stenberg|, A.K. Sternbeck|, E. Ulander|, M. Albertella|, R. Bethell|

PB-023 CRISPR-mediated base editing screens to identify PARP inhibitor resistant mutations
D. Krastev|, S. Pettit|, C. Lord|

PB-024 Investigating the effect of replication stress and other phenotypic factors as determinants of sensitivity to single agent ATR inhibitor, VE-821 in ovarian cancer cell lines
A. Bradbury|, D. King|, H. Bryant|, F. Zenke|, Y. Drew|, N. Curtin|

PB-025 Deacetylase activity of Sirtuin1 is required to protect the genome by preventing excess replication origin initiation
A. Baris|, H. Fu|, B. Thakur|, S. Jang|, C. Redon|, P. Kiran|, A. Mirit|

PB-026 ATM mRNA expression, somatic mutation counts, and survival in breast and gastric cancer
K.H. Lee|, S. Koung Jin|, K. Kwangsoo|, C. Seongmin|, K. Seongyeong|, M. Ahrum|, K. Tae-Yong|, I. Seock-Ah|

PB-027 High-throughput combinatorial CRISPR-Cas9 gene knockout and novel analysis platform to identify therapeutically-relevant synthetic lethal interactions

J.P. Shen|, B. Munson|, P. Mali|, T. Ideker|

PB-028 Targeting the DNA damage response via chemical exhaustion of replication protein A (RPA): Development and anti-cancer activity of small molecule RPA inhibitors.
J. Turchi|, N. Gavande|, P. VanderVere-Carozza|, K. Pawelczak|

PB-030 Clinical implications of Next Generation Sequencing-based somatic BRCA1/2 mutation profiling in consecutive ovarian carcinoma cases.
A. Kowalik|, K. Zalewski|, J. Kopczyński |, P. Macek|, M. Lech|, J. Kalisz|, K. Hińcza|, S. Zięba|, M. Misiek|, S. Góźdź|

PB-031 Biomarker Development in Ovarian Cancer Using Multispectral Immune Profiling of the DNA Damage Response
H. Robinson|, L. Gentles|, C. Kirk|, H. Smith|, L. Wilson|, N. Curtin|, R. O'Donnell|

PB-032 Free-circulating tumor DNA of JAM3 promoter methylation in colorectal cancer
W. Tang|, H. An|, D. Zhou|, L. Chen|, M. Cai|, F. Ye|, X. Lv|

Tue 13 Nov
Exhibition Hall -

Poster Session: Molecular Targeted Agents - PART I

PB-033 Four-weeks preoperative use of tocotrienol (delta-T3) from Annatto Bixa Orellana L. (Achiote tree) in breast cancer patients
C. Ferraris|, C. Listorti|, B. Ballestra|, A. Gambaro|, L. Rivoltini|, L. Mariani|, G. Martelli|, E. Tagliabue|, M. Giussani|, I. Maugeri|, S. Folli|, P. Limonta|, F.M. Celotti|

PB-034 RENCA Macrobead Therapy in Advance mCRC: Phase IIa and IIb Preliminary Multi-Site Tumor Marker Findings and Comparison of Patients Treated with RMB vs. Hospice Care
A. Nazarian|, S. Sureshbabu|, Z.P. Andrada|, J. Thomas|, N. Berman|, D.J. Wolf|, L.H. Gazda|, T.J. Fahey|, A.J. Ocean|, C.P. Comfort|, B.H. Smith|

PB-035 Androgen Receptor regulation of HGF/Met pathway in clear cell renal cancer
D. De Silva|, A. Roy|, M. Lee|, R. Costello|, D. Bottaro|

PB-036 Discovery of a potent androgen receptor degrader for castration resistant prostate cancer
C. Wang|, X. Han|, E. Fernandez-Salas|, C. Qin|, W. Xiang|, T. Xu|, D. McEachern|, S. Przybranowski|, C. Foster|, L. Bai|, J. Lv|, L. Huang|, S. Wang|

PB-037 Combination effect of thymoquinone and extracts of Iksan526 callus in A375 human melanoma cell line
S.J. Kim|

PB-038 HMBD001-10D1, a novel humanized anti-HER3 antibody with a unique mechanism of action, demonstrates superior tumor inhibition in multiple tumor models compared to other EGFR family therapies
D. Thakkar|, M. Taguiam|, V. Sancenon|, S. Guan|, K. Paszkiewicz|, P. Ingram|, J. Boyd-Kirkup|

PB-039 Broad spectrum activity of sabutoclax in haematological and solid cancer cell lines is associated with defined biomarkers
V. Vuaroqueaux|, H. Al Hasani|, G. Kelter|, H.R. Hendriks|, H.H. Fiebig|

PB-075 Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
J. Sorrentino|, J. Bisi|, D. Thompson|, A. Lai|, J. Strum|, P. Roberts|

PB-040 Inhibitors of p38 MAPK and MK-2 signaling pathways sensitize NCI-H69 cells to etoposide treatment
D. Alimbetov , B. Umbayev , T. Davis , S. Askarova , D. Kipling

PB-041 Tumor immune modulation by the PI3-kinase (PI3K) inhibitor MEN1611 via tumor-associated macrophages polarization
S. Capano|, A. Fiascarelli|, A.M. Tomirotti|, A. Paoli|, M. Bigioni|, A. Bressan|, D. Bellarosa|, M. Salerno|, M. Binaschi|

PB-042 Rational-based drug design of novel, highly potent MER inhibitors as potential treatment of cancers
A. Mikolajczyk|, A. Yamani|, P. Olejkowska|, N. Piorkowska|, M. Naitana|, P. Maliszewski|, K. Dubiel|, J. Pieczykolan|, M. Wieczorek|, A. Stanczak|

PB-043 Combining NAE inhibition and IAP antagonism leads to apoptosis through enhanced NF-kB inhibition in DLBCL cells and demonstrates potent anti-tumor activity in a preclinical DLBCL model
G. Ward|, A. Miura|, T. Smyth|, H. Muraoka|, J. Lyons|, A. Hashimoto|, R. Ferraldeschi|, Y. Nakatsuru|, M. Sims|, S. Ohkubo|, S. Jueliger|, C. Yoshimura|

PB-044 Combining novel STAT3 inhibitor YHO-1701 with multi-targeted tyrosine kinase inhibitor sorafenib improves anti-tumor response in solid tumor xenograft model
K. Taniguchi|, F. Nishisaka|, M. Tsugane|, G. Hirata|, A. Takagi|, S. Ishii|, H. Takahashi|, T. Iijima|, A. Asai|, T. Matsuzaki|, Y. Shishido|

PB-045 Distinct relationship of antitumor activity of lenvatinib (LEN) and sorafenib (SOR) to FGF21 expression levels in preclinical hepatocellular carcinoma (HCC) models
S. Watanabe Miyano|, H. Taisuke|, J. Ito|, K. Kodama|, H. Watanabe|, K. Takase|, J. Matsui|, Y. Funahashi|, K. Nomoto|

PB-046 Towards in vitro oncology trials: drug testing in breast patient-derived organoid cultures
L. Badder|, B. Herpers|, E. Knight|, R. Marlow|, S. Pettitt|, D. Larcombe-Young|, E. Francesch-Domenech|, M. Lomzik-Borowik |, A. Rushton|, W. Vader|, K. Yan|, D. Novo|, L. Price|, C. Lord|, A. Tutt|

PB-047 An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models
S. Hu|, J. Marineau|, M. Bradley|, K. Hamman|, S. Alnemy|, D. Smith|, J. Carulli|, C. Chuaqui |

PB-048 Establishment of a methodological platform for the exploration of MCL1 inhibitors
J. Ehlert|, D. Müller|, S. Umber|, C. Heidemann-Dinger|, C. Ketterer|, A. Chakrabarti|, D. Feger|, O. Siedentopf|, M. Birkle|, C. Schächtele|, M.H. Kubbutat|

PB-049 Involvement of Notch signaling pathway in a panel of human cancer cell lines
L. Astorgues-Xerri|, M. Martinet|, E. Raymond|, S. Faivre|, A. Tijeras-Raballand|

PB-050 Evaluation of drug–drug interaction of itraconazole and ivosidenib (AG-120), an oral, potent, targeted, small molecule inhibitor of mutant IDH1, in healthy subjects
B. Fan|, C. Prakash|, H. Liu|, G. Liu|, C. Korth|, H. Yang|, D. Dai|

PB-051 Mutant p53 As A Therapeutic Target for the Treatment of Triple-Negative Breast Cancer
N. Synnott , J Crown, M.J. Duffy

PB-052 CPL-410-005, a novel ubiquitin-activating enzyme (UAE) inhibitor in preclinical evaluation as an anticancer treatment for solid tumors
D. Kozlowska|, A. Gornicka|, B. Stypik|, M. Mroczkiweicz|, A. Mikolajczyk|, J. Hucz-Kalitowska|, A. Szwalbe|, K. Mulewski|, D. Smuga|, K. Dubiel|, J. Pieczykolan|, M. Wieczorek|, A. Stanczak|

PB-053 Aspartate-glutamate mitochondrial carrier’s contribution to the energetic balance during carcinogenesis
S. Rabinovich|, A. Silberman|, A. Bahat |, S. Levin-Zaidman|, Z. Porat|, D. Helbling|, D. Dimmock|, A. Erez|

PB-054 Co-Targeting ER and FGFR in patients with ER+/HER2- FGFR amplified (amp) Metastatic Breast Cancer (MBC)
K. Jhaveri|, U. Syed|, S. Wong|, G. D'Andrea|, D. Lake|, S. Goldfarb|, D. Gajria|, L. Ligresti|, A. Rogado|, J. Reis-Filho|, S. Chandarlapaty|

PB-055 Overcoming resistance to AKT inhibition in Oesophageal Adenocarcinoma
L. Cairns|, L. Stevenson|, R. Douglas|, N. McCabe|, E. Sutton|, R. Kennedy|, T. Harrison|, R. Turkington|

PB-057 Cyclin dependent kinase inhibition: a novel treatment strategy for glioblastoma
B. Murphy|, J. Noonan|, M. Jarzabek|, F. Lincoln|, B. Kavanagh|, P. Arhona|, L. Young|, K. Ligon|, H. Jahns|, A. Ashkenazi|, D. Zheleva|, J. Prehn|, M. Rehm|, A. Byrne|

PB-058 The novel oral Cdc7 inhibitor, SRA141, demonstrates robust efficacy in preclinical cancer models
R. Hansen|, S. Milutinovic|, B. Strouse|, M. Hedrick|, G. Smith|, C. Hassig|

PB-059 Modulation of OATP1B1 function by LYN-kinase inhibitors
S. Hu|, M. Chen |, A. Gibson|, A. Sparreboom |, J. Sprowl |

PB-060 Targeting the inhibitor of apoptosis proteins (IAPs) sensitises oesophageal adenocarcinoma to Akt inhibition
L. Stevenson|, L. Cairns|, R. Douglas|, N. McCabe|, G. Gavory|, T. Harrison|, R.D. Kennedy|, R.C. Turkington|

PB-061 Development of Limited Proteolysis, a Novel Drug Target Deconvolution Strategy
N. Beaton|, R. Bruderer|, K. Beeler|, I. Piazza|, L. Reiter|

PB-063 Relationship between c-kit mRNA expression and prognosis in postoperative patients with rectal carcinoma.
Y. Lin , Y. Huang , M. Ying

PB-064 Cell-penetrating Alphabodies targeting the Wnt/β-catenin pathway.
S. Loverix|, S. Pandolfi|, S. Deroo|, J. Desmet|, T. Girardi|, L. Wurth|, K. Vandenbroucke|, I. Lasters|, Y. McGrath|

PB-065 Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell lines
A. Estrada-Bernal|, A.T. Le|, A.E. Doak|, R.C. Doebele|

PB-066 In-vitro characterization of the mechanism of action of abemaciclib in human bone marrow progenitors
M.P. Ganado|, R. Torres-Guzman|, G.E. Perez|, C. Baquero|, S. Barriga|, B. San Antonio|, J. Du|, L. Prieto|, A. De Dios|, M.J. Lallena|

PB-067 CRISPR/Cas9 mutagenesis invalidates multiple drug targets in clinical testing
A. Lin|, C. Giuliano|, J. Sheltzer|

PB-068 Molecular dissection of CDK4/CyclinD1 regulation: Prevention of pathway hyperactivation by continuous CDK4/6 inhibition
S. Gharbi|, J. Gutierrez|, A. Espada|, S.M. Gutierrez|, R. Torres-Guzmán |, M.F. Debets|, L. Prieto|, J. Du|, A. De Dios|, M.J. Lallena|

PB-069 EGFR-mediated alterations to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (T-ADCC) in TKI-resistant HER2+ breast cancer cell lines.
N. Gaynor|, A. Canonici|, M. McDermott|, J. Crown|, D. Collins|

PB-070 Chromosomal Aberrations in Chronic Myeloid Leukemia: Response to conventional tyrosine kinase inhibitors and risk of blastic transformation.
S. Maqsood|, N. Siddiqui|, F. Ali|

PB-071 DCC-2618, a broad-spectrum inhibitor of KIT and PDGFRA mutants, synergizes with inhibitors of the MAPK pathway
A. Gupta|, C. Leary|, A. Garcia-Valverde|, J. Arribas|, C. Serrano|, D. Flynn|, B. Smith|

PB-072 RX-5902, a Beta-catenin Modulator, Enhances Immunotherapy Through Positive Alterations in the Tumor Immunologic Environment in Preclinical Models of Triple Negative Breast Cancer
J. Tentler|

PB-073 Targeting the AKT/mTOR/STAT3 pathways through a ROS-dependent Ubiquitin proteasome degradation in breast cancer by the natural polyphenol compound, carnosol
R. Iratni|, A.S. Halima|, E.H. Hussain|, A. Khawlah|, B. Nehla|, B. Mujeeb Zafar|, A.D. Yusra|

PB-074 Targeting CD205-positive solid tumors with a novel antibody drug conjugate (ADC): OBT076/MEN1309 target expression and activity guides Ph1 trial design
A. Kaplan|, N. Attanasio|, A. Bisht|, L. Deban|, S.L. Lou|, J. Berry |, R. Dusek|, R. Boyd|, M. Binaschi|, A. Pellacani|, E. Zhukovsky|, C. Rohlff|, A. Fandi|

PB-076 Expedited Development of AVB-S6 through the use of a Proprietary Biomarker in Healthy Volunteers to Guide Dosing in Oncology Studies
G. Mcintyre|, L. Bonifacio|, D. Prohaska|, J. Shang|, Y. Yokota|, A. Moss|, M. Dodds|, R. Tabibiazar|, A. Giaccia|

PB-077 Somatic mutations in vulvar squamous cell carcinoma and its premalignant lesions.
A. Kowalik|, S. Zięba|, N. Rusetska|, K. Zalewski|, A. Piaścik|, E. Bakuła-Zalewska|, J. Kopczyński|, M. Kowalewska|

PB-078 Targeting co-regulators of the Androgen Receptor as a novel therapeutic approach for prostate and breast cancer
M. Prencipe|, A. Fabre|, E. Corey|, W. Gallagher|, W. Watson|, J. Crown|

PB-079 Real-world practice for non-small cell lung cancer with targetable genetic alterations in an Irish setting
W. Mullally|, W. Kee|, C. Dennehy|, J. Greene|, D. Kelly|, R.M. Bambury|, B.R. Bird|

PB-080 L-Glutamine’s role in the anticancer activity of 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in non-small cell lung cancer (NSCLC) involving the CNS
L. Morgan|, R. Weiner|, T. Mahmood|, M. Ware|, A. Rodgers|, E. Benes|

PB-081 Co-targeting BRAF and Src family kinases in BRAF-mutant melanoma can provide superior control to block the emergence of BRAF inhibitor-resistant melanoma
C. Feddersen|, A. Varzavand|, J. Schillo|, M. Milhem|, Y. Zakharia|, M. Henry|, A. Dupuy|, C. Stipp|

PB-082 Intervenolin, a novel anti-tumor drug, suppresses cancer cell growth through modulation of tumor microenvironment
M. Kawada|, J. Yoshida|, M. Amemiya|, H. Abe|, T. Watanabe|, D. Tastuda|, M. Shibasaki|

PB-083 MERTK-driven oncogenecity in bladder cancer
A. Roy|, D.M. De Silva|, M.M. Lee|, R. Costello|, A.B. Apollo|, D.P. Bottaro|

PB-084 BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive gastric cancer
J.C. Yu|, W. Tang|, X. Deng|, Z. Ou|, J. Gan|, Q. Dong|, B. Tan|, L. Lu|, B. Chen|, C. Bao|, B. Thomas|, S. Li|

PB-085 Chemotherapy-induced metastasis: mechanisms and translational opportunities
G. Karagiannis|, L. Rivera Sanchez|, Y. Wang|, V. Sharma|, J. Burt|, D. Entenberg|, M. Oktay|, J. Condeelis|

PB-086 Cell cycle intervention beyond palbociclib; preclinical discovery of the CDK2/4/6 inhibitor PF-06873600
S. Dann|, K. Freeman-Cook|, N. Miller|, R. Hoffman|, J. Chionis|, K. Eisele|, Z. Qin|, C. Liu|, B. Murray|, M. Xu|, S. Ninkovic|, S. Sutton|, D. Behenna|, J. Solowiej|, P. Wei|, S. Weinrich|, N. Asako|, N. Huser|, C. Zhang|, R. Visswanathan|, B. Boras|, T. VanArsdale|, M. White|

PB-087 Inhibiting multifunctional ERK-protein complexes for cancer therapy
T. Kaoud|, W.H. Johnson|, N.D. Ebelt|, A. Piserchio|, S.V. Ravenstein|, D. Zamora-Olivares|, R. Edupuganti|, R. Sammons|, M. Cano|, M. Warthaka|, C.D. Tavares|, J. Park|, P. Ren|, R. Ghose|, K.Y. Tsai|, E.V. Anslyn|, K.N. Dalby|

PB-088 EVT601, an allosteric modulator of FGFR with an unprecedented irreversible mechanism of action: the next generation of anti-FGFR therapy?
C. Alcouffe|, G. Gueguen-Dorbes|, P. Fons|, F. Dol-Gleizes|, D. Sibrac|, F. Comitani|, F.L. Gervasio|, M. Whittaker|, C. Herbert|

PB-089 Differential Dependency of BRAF-mutant Melanoma on ERK2 Versus ERK1
M. Crowe|, T. Zavorotinskaya|, C. Voliva|, D. Stuart|, A. Freeman|

PB-090 Development of inhibitors of the activated form of KRAS G12C
R. Pollock|, M. Stewart|, N. Perl|, S.J. Lee|, L. Xue|, M. Zhou|, J. Simon|, K. Luly|, S. Grigoriu|, A. Yuzhakov|, A. Silver|, J. Lowe|, A. Mann|, G. Verdine|, A. Rigby|, M. Mulvihill|, E. May|, A. Kohlmann|, S. Townson|, M. Jin|

PB-091 Cell panel profiling yields additional drug response biomarkers for kinase inhibitors approved for clinical use
J.C.M. Uitdehaag|, J.J. Kooijman|, J.A.D.M. de Roos|, M.B.W. Prinsen|, J. Dylus|, N. Willemsen-Seegers|, D.M. Jos|, S.J.C. van Gerwen|, R.C. Buijsman|, G.J.R. Zaman|

PB-092 Augmented apoptosis and DNA damage by the combined inhibition of CHK1 and PI3K/mTOR pathway in high-grade serous ovarian cancer (HGSOC)
T.T. Huang|, E. Brill|, C.J. Thomas|, J.M. Lee|

PB-093 Preclinical CDK4/6 inhibition for squamous cell carcinoma of the head and neck
G. van Caloen|, S. Schmitz |, X. Caignet|, M. El Baroudi|, J.P. Machiels|

PB-094 Simultaneous Molecular Alterations and Clinical Outcomes in Solid Tumors with IDH1 or IDH2 Mutations
A. Swilling|, J. de Groot|, M. Javle|, M. Penas-Prado|, R. Shroff|, R. Luthra|, K. Banks|, R. Lanman|, A. Conley|, R. Broaddus|, M. Davies|, S. Kopetz|, W.A. Yung|, J. Heymach|, S. Fu|, K. Shaw|, F. Meric-Bernstam|, F. Janku|

PB-095 Autophagy dependence of small molecule angiokinase inhibitors in colorectal cancer (CRC)
A.K. Larsen|, P. Mésange|, M. Sabbah|, L. Louadj|

PB-096 Influence of the epithelial-mesenchymal transition (EMT) on the response to VEGF-targeted agents in first- and second-line treatment of colorectal cancer
A.K. Larsen|, L. Louadj|, S. Thouroude|, B. Chibaudel|, J.P. Thiery|, J. Denis|, A. de Gramont|, A. Bouygues|

PB-097 Novel c-kit exon 9 mutations in GISTs: is imatinib good for bad?
E. Laurini|, S. Aulic|, M. Fermeglia|, R. Riboni|, M. Lucioni|, E. Dellera|, M. Alessiani|, V. Perfetti|, S. Pricl|

PB-098 Impact of regulatory T cells on cellular cytotoxicity induced by ERY974, a novel T cell–redirecting bispecific antibody targeting glypican-3
Y. Sonobe|, Y. Miyazaki|, Y. Sano|, Y. Kinoshita|, Y. Azuma|, T. Tsunenari|, T. Ishiguro|, S. Kishishita|, M. Endo|, J. Nezu|

Tue 13 Nov
Exhibition Hall -

Poster Session: Oncolytic viruses

PB-099 Clinical and correlative data from a first-in-human (FIH) study of the intratumoral (IT) oncolytic virotherapy Voyager-V1 (VV1) in patients (pts) with refractory solid tumors
M. Patel|, S. Powell|, J. Merchan|, J. Strauss|, T. Cripe|, M. Old|, A. Bexon|, R. Diaz|, M. Reckner|, L. Russell|, N. Packiriswamy|, B. Bethany|, D. Upreti|, R. Khan|, L. Suksanpaisan|, R. Vandergaast|, K.W. Peng|, S. Russell|

Tue 13 Nov
Exhibition Hall -

Poster Session: Vaccination

PB-100 Novel Apolipoprotein-A1 (ApoA-I) multimers, Cargomer®, as new targeted delivery platform for therapeutic cancer vaccines with tumor neo- and shared-antigens
V. Albinet|, E. Lacoste|, R. Baron|, R. Palmantier|, M. Frohlich|, J.L. Dasseux|